Related references
Note: Only part of the references are listed.Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer
Eliza Hawkes et al.
EUROPEAN JOURNAL OF CANCER (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
A Phase II Study of Irinotecan, Continuous 5-Fluorouracil, and Leucovorin (FOLFIRI) Combination Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer Previously Treated With a Fluoropyrimidine-Based Regimen
Seok Hyun Kim et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
N. C. Tebbutt et al.
BRITISH JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Is there a role for second-line chemotherapy in advanced gastric cancer?
Robert Wesolowski et al.
LANCET ONCOLOGY (2009)
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
Narikazu Boku et al.
LANCET ONCOLOGY (2009)
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
Sun Jin Sym et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I/II study of docetaxel and S-I in patients with advanced gastric cancer
K. Yamaguchi et al.
BRITISH JOURNAL OF CANCER (2006)
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
S. R. Park et al.
BRITISH JOURNAL OF CANCER (2006)
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
KF Giordano et al.
ANNALS OF ONCOLOGY (2006)
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer
Kazuhiro Yoshida et al.
CLINICAL CANCER RESEARCH (2006)
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
JA Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma:: A randomized phase II study
PC Thuss-Patience et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:: results of a randomized phase II study
C Pozzo et al.
ANNALS OF ONCOLOGY (2004)
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
L Assersohn et al.
ANNALS OF ONCOLOGY (2004)
Irinotecan is active in chemonaive patients with metastatic gastric cancer:: a phase II multicentric trial
CH Köhne et al.
BRITISH JOURNAL OF CANCER (2003)
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia
A Jatoi et al.
JOURNAL OF GASTROINTESTINAL CANCER (2002)
Share Paper
